Latest Headlines

Latest Headlines

Protalix flips its Gaucher drug to Pfizer for $46M in R&D cash

Israeli drug developer Protalix BioTherapeutics is backing away from its sole approved drug, selling the majority rights to partner Pfizer and pledging to invest the proceeds in its pipeline.

Big Pharma stands back as little guys work on plant-based drugs and manufacturing

When it comes to manufacturing, Big Pharma prefers traditional plants to living plants. While drugs manufactured from plants like tobacco have been in the news because several makers of Ebola drug candidates are using the process, the method has not been embraced by any of the major players.

Specialized manufacturing technology punches ticket to Protalix's value

Protalix BioTherapeutics developed Gaucher disease drug Elelyso, which it partnered on with Pfizer, but it may be the rare disease drug's unique plant cell-based manufacturing system that is making the small Israeli biotech potentially worth $1 billion.

Pfizer partner Protalix soars on sale speculation

With pharma interest in rare-disease drugs becoming quite common, Protalix BioTherapeutics, maker of a rare disease drug partnered with Pfizer ($PFE), said today that it has hired Citigroup to help review "a broad array of product partnering, technology sharing and other strategic alternatives" for the Israel-based biotech company.

EU regulators shut out new Gaucher drug from Pfizer, Protalix

Just weeks after winning U.S. approval for their new Gaucher drug taliglucerase alfa, the EMA's Committee for Medicinal Products for Human Use says Pfizer and Protalix BioTherapeutics should be shut out of the EU in order to honor Shire's exclusive status for its currently used Vpriv.

Protalix scores $25M milestone from Pfizer

Pfizer followed GlaxoSmithKline and other pharma companies that journeyed into the rare disease arena, paying $60 million upfront to partner with Protalix and agreeing to pay out up to $55 million in milestones.

FDA OK for Gaucher drug opens new market for Pfizer, Protalix

After initially being rebuffed at the FDA Pfizer and Protalix have snagged an FDA OK for their new Gaucher disease drug Elelyso (taliglucerase).

Protalix shares dive on Gaucher's drug delay at FDA

Protalix BioTherapeutics ($PLX) reported this morning that the FDA is putting off its deadline for a final decision on its drug for Gaucher's disease. The new deadline is May 1, and the news quickly

Genzyme's shortage opens door to rival Protalix

Manufacturing remediation chugs along at Genzyme, which anticipates some supply constraints of Gaucher-disease treatment Cerezyme before the supply outlook improves in February. Operating under a

Protalix showcases PhIII data for rare-disease drug in Pfizer pact

Amid its latest run for FDA approval of its Gaucher disease drug tied into a collaboration with Pfizer ($PFE), Protalix BioTherapeutics ($PLX) has published details from its Phase III package that